A phase I/II trial using Tr1 cell clones in patients displaying severe Crohn disease, yielded encouraging results [58] and a dose-escalation trial using autologous ex vivo expanded polyclonal Tregs (CD4+CD25+CD127-/lo) in diabetes patients is currently ongoing [59]. This evidence concerns the gene CD4 and Crohn disease.